Login to Your Account



NewCo News

GT Biologics Set to Move Crohn’s Drug into Phase I

By Nuala Moran
Staff Writer

Wednesday, October 16, 2013

LONDON – GT Biologics Ltd. is poised to become a pioneer of the new drug class of live biotherapeutics after receiving orphan drug status from the FDA for Thetanix, a bacterial treatment for pediatric Crohn’s disease.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription